Login to Your Account



Other News To Note


Wednesday, November 16, 2011
• Concert Pharmaceuticals Inc., of Lexington, Mass., said it inked a research collaboration with the National Institutes of Health's Therapeutics for Rare and Neglected Diseases (TRND) program to advance the firm's deuterium-modified praziquantel program as a potential treatment for schistosomiasis, a disease caused by parasitic worms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription